Depo Provera 500 is a specialized synthetic hormonal agent used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. The drug's primary therapeutic uses are recognized in clinical practice for specific hormonal interventions.

Supportive Management in Select Oncological Conditions

This medication is commonly used to help with specific forms of cancer that require hormonal intervention, such as certain cases of endometrial or renal cell carcinoma. It is relevant in contexts marked by increased discomfort or tension, and where this type of therapy is considered appropriate. This therapy may be part of symptomatic management in conditions presenting with systemic or localized discomfort.

Applied Across Domains Requiring Additional Symptomatic Support

Depo Provera 500 helps address symptom clusters related to systemic imbalance, such as anorexia (severe lack of appetite) and cachexia (unintended weight loss) associated with advanced illness. This use provides support that generally helps ease the overall symptom burden, and may assist with maintaining functional stability when symptoms create noticeable physiological strain.

Relief of Disruptive Gynaecological Symptoms

The drug is relevant for managing symptoms that become more disruptive during flare-ups in conditions like endometriosis, which is characterized by periods of heightened symptoms. It is applied in scenarios where additional management of discomfort is required for symptoms related to chronic pelvic pain and abnormal uterine bleeding, and supports general well-being during symptomatic phases.

---

“The therapy may contribute to easing the overall symptom load during periods of heightened symptoms.”

---

Quick Fact: Relevant for Anorexia and Chronic Pain Management

---

This medication may be part of symptomatic management in conditions presenting with systemic or localized discomfort, offering assistance in symptom stabilization.

The eligibility for Depo-Provera 500 is strictly defined by regulatory guidelines, focusing on populations with specific hormone-sensitive conditions, such as certain cases of endometrial or renal cell carcinoma. Use is generally restricted to adult patients.

Contraindicated Populations

Official labeling absolutely prohibits the use of this medicine in the following populations:

• Patients with known or suspected pregnancy or those with undiagnosed vaginal bleeding.
• Individuals with active or history of thromboembolic disorders (e.g., blood clots, cerebral vascular disease).
• Those with severe liver dysfunction or significant liver disease.
• Patients with a known or suspected malignancy of the breast or a meningioma.
• Patients with known hypersensitivity to the active ingredient or excipients.

Age and Condition Restrictions

Classification	Eligibility Status
Pediatric Patients (children)	Safety and efficacy have not been established for high-dose indications; not indicated before menarche.
Pregnancy/Lactation	Contraindicated in pregnancy; Caution is required during lactation (breastfeeding).
Comorbidities	Patients with diabetes mellitus or those with risk factors for osteoporosis must be closely monitored.

Regulatory criteria mandate that the medicine must be discontinued immediately if pregnancy is suspected or if a thromboembolic event occurs. Eligibility is not established for all populations and requires strict adherence to documented exclusion criteria.

Interaction Map: Interactions with other medicines and products — official regulatory information for Depo Provera 500

• Medicinal product categories with documented interactions: Cytochrome P450 3A4 (CYP3A4) Inducers and Inhibitors, Antidiabetic Therapy, and substances that alter Medroxyprogesterone Acetate (MPA) plasma levels.
• Specific interacting medicines explicitly listed: Aminoglutethimide, Rifampin, Phenytoin, Carbamazepine, Phenobarbital, Ketoconazole, and Ritonavir are noted in regulatory materials.
• Mechanistic basis of interactions: MPA is primarily metabolized by hydroxylation via the CYP3A4 enzyme system. This classification defines the clinically significant potential for exposure modification.

Official Interaction Statements:

Co-administration with strong CYP3A4 inducers (e.g., Rifampin, Phenytoin) is officially expected to decrease MPA concentrations. The specific drug Aminoglutethimide is documented to significantly depress MPA serum levels, resulting in a risk of decreased efficacy. Conversely, strong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir) are expected to increase MPA concentrations.

A pharmacodynamic interaction is documented with antidiabetic therapy, noting that MPA is linked to a decrease in glucose tolerance. For supplemental products, the herbal product St. John's wort is documented as an enzyme inducer that may reduce MPA plasma concentrations. No mandatory administration timing separation rules are documented. A population-specific caution notes that MPA may be poorly metabolised in patients with severe liver insufficiency.

Connection to the overall interaction profile: Regulatory documents define the interaction structure primarily through the CYP3A4 metabolic pathway, establishing that the co-administration of inducers leads to a reduction in systemic exposure, while inhibitors result in an increase in exposure. This high-level, pharmacokinetic profile dictates the constraints noted in official labeling.

Medroxyprogesterone acetate (MPA), the active pharmaceutical ingredient, is a synthetic progestin that functions as an agonist at the intracellular progesterone receptor (PR), predominantly PR-A and PR-B isoforms. Upon intramuscular injection, the compound forms a depot, providing sustained systemic exposure.

Molecular and Cellular Pathways

MPA binds the progesterone receptor in target tissues, including the hypothalamus, pituitary gland, and female reproductive tract. This ligand-receptor complex translocates to the nucleus, where it modulates gene transcription by interacting with hormone response elements (HREs). The primary pathway involves suppression of the hypothalamic-pituitary-ovarian (HPO) axis.

Downstream Cascades and System-Level Consequences

In the pituitary, the binding of MPA to PR inhibits the release of gonadotropins, specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This antigonadotropic effect prevents the physiological LH surge, resulting in the inhibition of follicular maturation and ovulation.

Systemically, MPA induces changes in the reproductive tract: it causes thickening of the cervical mucus, which physically impedes the transit of spermatozoa, and promotes atrophic changes in the endometrium by repressing estrogen-driven cellular proliferation.

Administration Process

Depo Provera 500 is a high-dose progestogen preparation. The administration of this medication is performed by a qualified healthcare professional. It is delivered via deep intramuscular injection, typically into the gluteal muscle (buttock) or the deltoid muscle (upper arm).

Preparation of the Injection

The medication is supplied as an aqueous suspension. Before administration, the vial or pre-filled syringe must be shaken vigorously to ensure that the active ingredient, medroxyprogesterone acetate, is uniformly resuspended. The liquid should appear as a white, homogenous suspension before the procedure begins.

Site Care

Following the injection, the site of administration should not be massaged. This ensures that the medication is released into the system at the intended rate from the muscle tissue. Rotating the injection site for subsequent doses is a standard practice to maintain tissue health.

Treatment Cycles

The timing and frequency of injections are determined by the specific clinical indication being treated. For oncology-related purposes, the schedule often involves an initial loading phase followed by a maintenance phase. Maintaining a consistent schedule is essential for therapeutic stability. If a scheduled dose is missed, healthcare providers determine the appropriate protocol for resuming the regimen based on the time elapsed since the last administration.

Research Evidence / Overview of Studies for Depo Provera 500

Evidence for Supportive Management of Cancer-Related Symptoms

Research has examined the use of this high-dose hormonal agent in adults with advanced cancer who are experiencing weight loss and poor appetite, a condition often called anorexia-cachexia syndrome (CACS). The primary evidence in this area comes from Randomized Controlled Trials (RCTs) and systematic reviews. The studies monitored outcomes related to systemic or functional imbalance, including changes in body weight, patient-reported appetite levels, and scores measuring Quality of Life (QoL). Studies reported data showing changes in body weight during the short-term follow-up. What remains uncertain is the specific composition of the weight change; data for determining whether the weight gain was associated with primarily lean body mass or other body components are still emerging or were mixed across studies.

Evidence for Hormonal Therapy in Endometrial and Renal Carcinoma

This medication was studied for use as a hormonal treatment in patients with specific forms of advanced cancer, namely recurrent or metastatic Endometrial Carcinoma (EC) and Renal Cell Carcinoma (RCC). The studies examined endpoints related to disease progression, such as the Overall Response Rate (ORR) and Progression-Free Survival (PFS). Studies reported patterns observed in the studies where tumor responses varied significantly and was associated with the presence of specific markers, like Progesterone Receptors (PR). The certainty around long-term outcomes for patients with tumors lacking these hormonal markers remains low.

Evidence for Managing Symptoms Associated with Endometriosis

Research has explored the use of this formulation in studies evaluating pain symptoms associated with visually confirmed endometriosis. This area of evidence is supported by Randomized Controlled Trials (RCTs). The studies monitored outcomes related to physical discomfort, primarily measuring changes in patient-reported pelvic pain scores over defined time intervals. Research highlights changes measured during the study period, with studies reporting that pain scores evolved in the observed populations. Follow-up durations were limited when examining the return of pain after treatment stopped.

Summary of Research Gaps and Uncertainties

Despite the existence of controlled trials, the evidence landscape for this high-dose formulation still presents several areas of uncertainty. Evidence quality varies across studies, and findings were mixed or limited by modest sample sizes. Research exploring long-term outcomes, particularly the sustained durability of changes observed and consequences beyond one year of treatment, is not fully established.

Key Studies & References Medroxyprogesterone acetate in the management of cancer cachexia

Common questions about Depo Provera 500 (FAQ)

Q: How quickly does Depo Provera 500 start to work for its main use?

Depo Provera 500 is specifically formulated as a depot injection, which means it is designed to release the medicine into the body slowly and steadily over time. While the exact time needed to reach the full therapeutic level can vary for each patient, the official product information indicates the active substance is intended to provide sustained release after the injection.

Q: How long do the effects of Depo Provera 500 last after one injection?

As a depot suspension, the medicine is intended to give the body consistent systemic exposure to the active ingredient over an extended period. Official product information indicates dosing schedules range from weekly to twice-weekly to maintain therapeutic levels, but the full duration of effect from a single dose is not precisely defined in patient-facing documents.

Q: Does Depo Provera 500 have long-term effects on the body?

Yes, regulatory documents highlight potential long-term effects. Prolonged use of the medicine is associated with a reduction in Bone Mineral Density (BMD), which is the strength and density of the bones. Furthermore, official labeling notes a potential increase in the risk of a non-cancerous brain tumor, meningioma, with long-term use, which is noted to be dose-dependent.

Q: What happens when the use of Depo Provera 500 is stopped?

When the injections are discontinued, the active substance continues to be released from the muscle injection site for some time. For the effect on bone density, studies indicate that a recovery period is necessary for the BMD to return toward previous values, though the time needed for recovery can vary, and full recovery to baseline may not always be achieved.

Q: Can Depo Provera 500 affect mood or cause emotional changes?

Yes, official safety information classifies certain changes as Psychiatric Disorders among the common side effects that can occur. These commonly reported effects include experiencing nervousness and depression.

Q: What are the official clinical expectations about weight change with Depo Provera 500?

Official safety documents indicate that weight increase is classified as a common side effect of the medicine. Additionally, research that supported the medicine’s use for certain cancer-related symptoms noted that patient populations experienced changes in body weight while on the treatment.

Q: Is it true that Depo Provera 500 can affect bone density?

Yes, official labeling explicitly highlights that extended or prolonged use of the medicine can lead to a significant loss of Bone Mineral Density (BMD), which measures the strength and density of the bones.

Q: Are there specific dietary restrictions while using Depo Provera 500?

General dietary restrictions are not mandated in the official product information. However, regulatory documents do note that the medicine is linked to a decrease in glucose tolerance (the body's ability to process sugar), which may be relevant for individuals with conditions requiring glucose level management.

Q: Can Depo Provera 500 affect a person's sleep pattern?

Yes, official safety documents indicate that a person's sleep pattern may be affected. Insomnia, or difficulty sleeping, is listed as a common side effect of the medicine.

Q: What is the role of Depo Provera 500 in treating conditions other than its primary use?

While primarily used as a palliative treatment for advanced hormone-sensitive cancers, the high-dose active ingredient has also been studied for other conditions. This includes its use in hormonal treatment for recurrent or metastatic endometrial and renal cell carcinoma, and research has explored its role in managing pain symptoms associated with endometriosis.

Q: Is Depo Provera 500 the same as other forms of Depo Provera?

No. The Depo Provera 500 formulation is a high-dose regimen primarily intended for oncology or specific palliative conditions. This is distinct from the lower-dose injectable formulation, such as the Contraceptive Injection, which is used for contraception. They share the same active ingredient but differ significantly in dosage and therapeutic purpose.

Q: What is the official safety classification of Depo Provera 500?

In the US, the official labeling contains a Boxed Warning that specifically highlights the serious risk of Bone Mineral Density (BMD) loss associated with the use of the medicine. This is a key component of the official safety information intended to draw attention to this potential effect.

Q: What level of pain at the injection site is considered typical with Depo Provera 500?

Official safety data lists injection site reactions, including pain, as a very common side effect, meaning it is observed in 1 out of every 10 people or more. However, the patient-facing classification does not define the intensity of the pain, such as labeling it as mild, moderate, or severe.

Q: Does Depo Provera 500 interfere with laboratory tests?

Yes. Regulatory documents note that the active ingredient may affect the results of specific laboratory tests. This includes tests that measure steroid levels and gonadotropin levels in the plasma and urine. It is important to inform medical personnel about treatment when undergoing these tests.

Q: How does Depo Provera 500 interact with herbal supplements?

The official interaction profile identifies that the herbal product St. John's wort is a known enzyme inducer. Co-administration of this supplement may lead to lower concentrations of the active ingredient, potentially reducing the medicine's effect.

Q: What are the known severe but rare side effects of Depo Provera 500?

Official safety data lists several rare side effects that are considered severe. These include Thromboembolic Events (the formation of blood clots), severe allergic reactions, and severe problems with hepatic function (liver function).

Q: Can Depo Provera 500 be used by individuals with kidney issues?

The official prescribing information does not generally specify dose adjustments for kidney impairment. However, caution is necessary for patients with pre-existing conditions like kidney or heart issues, due to the fluid retention possibility noted in regulatory documents.

Q: What is the information available on patient quality of life while on Depo Provera 500?

Research studies that examined the use of the medicine for certain cancer-related symptoms included the monitoring of outcomes related to patient-reported Quality of Life (QoL) scores. While QoL was monitored, official information available to the public does not typically provide a general summary statement about the overall changes in quality of life observed across all studies.

Q: Do studies show that Depo Provera 500 has a consistent effect across all users?

Official information suggests a non-uniform response. Research has indicated that responses to treatment, especially when used for certain cancers, varied significantly among different patients and were often linked to individual patient characteristics, such as the presence of specific hormonal markers in tumors.

Q: What is the guidance for using Depo Provera 500 in individuals with diabetes?

The eligibility criteria notes that patients with diabetes mellitus should be closely monitored while receiving this medicine. This is due to the documented link between the active ingredient and a potential decrease in glucose tolerance.

Q: Why do some people confuse Depo Provera 500 with birth control?

The confusion arises because the active pharmaceutical ingredient, medroxyprogesterone acetate, is also used in a separate, much lower-dose injectable formulation that is widely prescribed for contraception (birth control). This overlap in the active ingredient leads to common confusion between the high-dose and low-dose formulations.

Q: Is Depo Provera 500 considered a long-acting injectable medicine?

Yes. The formulation is officially classified as a Depot Formulation. This specific design allows for the slow, sustained release of the drug from the muscle tissue over an extended period, which aligns with the properties of a long-acting injectable medicine.

Q: What is the difference between Depo Provera and Provera tablets?

Both products contain the same active ingredient, medroxyprogesterone acetate (MPA). The key difference is the form and route of delivery: Depo Provera is an injectable suspension designed to create a long-acting depot effect, while Provera is an oral tablet formulation.

Q: What are the research findings regarding Depo Provera 500 and headaches?

Official safety data lists headache as a very common adverse reaction associated with the use of the medicine, meaning it is an effect observed in 1 out of every 10 people or more. The frequency classification indicates it is one of the most frequently observed side effects.

Q: Why do official documents mention possible hair loss as a side effect?

Official safety documents list hair loss (alopecia) as an uncommon side effect associated with the use of the medicine. Listing the effect indicates that it was observed in clinical studies, occurring in fewer than 1 in 100 people but more than 1 in 1,000 people.

Q: What research exists on the effect of Depo Provera 500 on cholesterol levels?

Regulatory documents state that the effects of the active ingredient on lipid metabolism (which includes cholesterol) are inconsistent. Studies have reported both increases and decreases in levels of total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol in patients.

How to Store and Dispose of Depo Provera 500

The sterile suspension of Depo Provera 500 (medroxyprogesterone acetate) must be stored at controlled room temperature, which is between 20^circ and 25 C (68^circ to 77 F). Vials should be kept in an upright position in their original container.

Because this medication is a suspension, it is essential to vigorously shake the vial or prefilled syringe just before use to ensure the dose is uniform.

To ensure proper disposal, do not flush this medication down a toilet or pour it into a drain. Depo Provera 500 is documented as being toxic to aquatic life, so preventing environmental release is necessary. All used materials and waste should be placed in an appropriately labeled, sealed container and disposed of according to local environmental regulations.